3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
8
Melanoma
4
Uveal Melanoma
3
Sarcoma
3
Leukemia, Myeloid, Acute
3
Glioblastoma
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Neoplasms
2
Mesothelioma, Malignant
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable Hepatocellular Carcinoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Leiomyosarcoma
1
Ichthyosis, X-Linked
1
HER2 Negative Metastatic Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Solid Cancers
1
Advanced Pancreatic Cancer
1
Interventions
Sorafenib
61
Bevacizumab
42
Oxaliplatin
24
Doxorubicin
22
Radiosurgery
20
Gemcitabine
20
Fluorouracil
20
Nivolumab
19
durvalumab
18
Radiofrequency Ablation
18
pembrolizumab
17
Capecitabine
17
lenvatinib
16
Cisplatin
16
atezolizumab
13
Leucovorin
13
Radiotherapy
11
tremelimumab
10
Cyclophosphamide
10
Carboplatin
10
Irinotecan
9
Ipilimumab
9
Drug Therapy
9
Everolimus
8
Cryosurgery
8
toripalimab
7
fludarabine
7
Sunitinib
7
Chemotherapy, Adjuvant
7
Melphalan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Liver Neoplasms
×
ADI PEG20
×
Clear all
NCT02006030
2018-09-04
TACE
Polaris Group
Phase 2
Completed
30 enrolled